Quick-Med forms distribution and manufacturing agreement with BASF
The new agreement builds on a prior one signed in June 2008 with BASF’s Beauty Care Solutions group, which is now being extended because of the growing popularity of the ingredient for cosmetic skin care formulations.
It will run from when the first agreement expired, in December 2010, through to December 2014.
“BASF Beauty Care Solutions is at the forefront of cosmetic ingredients research and its new Noctafix ingredient can leverage Multistat’s exciting anti-aging potential,” said Ladd Greeno, CEO of Quick-Med Technologies.
MultiStat inhibits MMPs
MultiStat is based on a family of matrix metalloproteinase (MMP) inhibitors - compounds that inhibit the production of MMPs.
However, according to Quick Med Technologies BASF will be concentrating on only one of the patented compounds in the family, called Ilomastat.
MMPs are enzymes that break down extracellular matrix proteins, performing many diverse functions. Their role in skin ageing is due to the fact that they degrade both collagen and elastin, leading to a loss of elasticity and firmness of human skin.
Reducing fine lines and wrinkles
The Multistat technology is said to be effective in broad-based cosmetic applications, having the effect of improving the appearance of fine lines and wrinkles that are associated with both natural aging and environmentally-induced photoaging.
The MultiStat technology was originally developed by the University of Michigan with whom Quick Med Technologies signed a license agreement in 2007.
It consists of over 10 patented compounds and patented formulae for developing other compounds.
Several other ingredients and technology providers have launched MMP inhibitor ingredients in recent years, including Soliance and Symrise.
